Question normal

We have seen an increase in the percent of drugs going through specialty/limited distribution networks- mainly oncology, MS, and other drugs. We have also seen costs of specialty drugs increase, and Turing pharmaceuticals used this strategy to limit other companies from accessing this drug. With the large number of oncology drugs set to come onto the market in the next 10 years, do you think we will see increased use of specialty distribution networks- what concerns, if any, should we have? Can you talk more about this?